Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H36O10 |
| Molecular Weight | 532.5794 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]1(COC(=O)CCC(O)=O)[C@@H](CC[C@]2(C)[C@@H]1CCC(=C)[C@H]2\C=C\C3=CCOC3=O)OC(=O)CCC(O)=O
InChI
InChIKey=YTHKMAIVPFVDNU-GPTWTFMPSA-N
InChI=1S/C28H36O10/c1-17-4-7-20-27(2,19(17)6-5-18-13-15-36-26(18)35)14-12-21(38-25(34)11-9-23(31)32)28(20,3)16-37-24(33)10-8-22(29)30/h5-6,13,19-21H,1,4,7-12,14-16H2,2-3H3,(H,29,30)(H,31,32)/b6-5+/t19-,20+,21-,27+,28+/m1/s1
Dehydroandrographolide (DP) from Andrographis paniculata (Burm. F.) Nees is a potential anticancer agent which can act, in part, through the inhibition of TMEM16A expression and may support TMEM16A as a novel target for antitumor therapy in TMEM16A-amplified cancers. It was shown that DP inhibits the invasion of human oral cancer cells and is a potential chemopreventive agent against oral cancer metastasis. It is also used for the treatment of infections in China. However, DP has not been found to significantly inhibit bacterial and viral growth directly. It was discovered that the DP enhanced innate immunity of intestinal tract through increased expression of human β -defensin-2 (hBD-2) through the p38 MAPK pathways. Dehydroandrographolide also possesses activity against hepatitis B virus
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification of the Novel TMEM16A Inhibitor Dehydroandrographolide and Its Anticancer Activity on SW620 Cells. | 2015 |
|
| Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp. | 2014-03-01 |
|
| Exploring Mn-doped ZnS quantum dots for the room-temperature phosphorescence detection of enoxacin in biological fluids. | 2008-05-15 |
|
| Dehydroandrographolide succinic acid monoester as an inhibitor against the human immunodeficiency virus. | 1991-05 |
Sample Use Guides
in mice: For experimental xenograft growth inhibition study, 5–6 week male BALB/c nude mice (18–22 g) were used. SAS cells (2 × 106 per mouse) were resuspended in 200 μl of sterile PBS and injected s.c. into the right flank of the mouse. Mice were randomized into two groups (5 mice/group). All animals were housed with a regular 12-h light/12-h dark cycle and water ad libitum access to standard rodent chow diet and kept in a pathogen-free environment at the Laboratory Animal Unit. Seven days after tumor cell injection, the mice were orally fed dehydroandrographolide (DA) (40 or 100 mg/kg) or vehicle three times per week.
Route of Administration:
Oral
Human intestinal epithelial HCT-116 cells were incubated with 1-100 μM Dehydroandrographolide (DA) for 2-24 h. RT-PCR and Western blot were used to assess the expression of human β -defensin-2 (hBD-2). The specific inhibitors were used and the levels of phosphorylation of signaling molecules were detected for dissecting the signaling pathways leading to the induction of hBD-2. MTT assay showed there was no obvious cytotoxicity for HCT-116 cells by 1-100 μM DA treatment. RT-PCR and Western blot assays showed that DA (1-100 μM) could up-regulate the expression of hBD-2, and the effect lasted longer than 24 h.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
786593-06-4
Created by
admin on Tue Apr 01 16:22:54 GMT 2025 , Edited by admin on Tue Apr 01 16:22:54 GMT 2025
|
PRIMARY | |||
|
0X50BP49M1
Created by
admin on Tue Apr 01 16:22:54 GMT 2025 , Edited by admin on Tue Apr 01 16:22:54 GMT 2025
|
PRIMARY | |||
|
6540717
Created by
admin on Tue Apr 01 16:22:54 GMT 2025 , Edited by admin on Tue Apr 01 16:22:54 GMT 2025
|
PRIMARY | |||
|
DTXSID901026359
Created by
admin on Tue Apr 01 16:22:54 GMT 2025 , Edited by admin on Tue Apr 01 16:22:54 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD
